Giuliana Autiero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giuliana Autiero has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Andrea Tavernese
Department of Internal Medicine, Angiology Unit, Ospedale dell’Angelo, Mestre-Venezia, Italy
1 shared publication- Cristiano Amarelli
Department of Cardiac Surgery and Transplants. Monaldi, A.O. dei Colli, Naples, Italy
1 shared publication Daniela Pinto
Unit of Internal Medicine & Transplants A.O.R.N. Ospedali dei Colli ‐ Ospedale Monaldi Napoli Italy
1 shared publicationElisabetta Grolla
Department of Cardiology, Ospedale dell’Angelo, Mestre-Venezia, Italy
1 shared publication- Emanuele Durante-Mangoni
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
1 shared publication - Fabian Patauner
Department of Precision Medicine, University of Campania 'L. Vanvitelli', and Unit of Internal Medicine and Transplants, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 25 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (8) , e70243
Conditions Associated With the Onset of Cancer After Heart Transplant: Longitudinal Study in 335 Recipients
Cancer is among the major causes of death after heart transplant (HTx). Risk factors for cancer occurrence in this setting are not well established. This was a retrospective observational study of patients who underwent HTx between 2006 and 2019 and were followed up until May 2024. Clinical variables possibly associated with cancer were assessed with univariable and multivariable analyses. Survival analysis was carried out drawing Kaplan Meier curves and a Cox regression with time‐varying covariates were performed to overcome the immortal‐time‐bias. Three‐hundred‐thirty‐five HTx recipients were included, of whom 42 (12.5%) developed cancer after a median of 6.3 years. In univariable analysis, older age at HTx, smoking history, alcohol use, male sex, ischemic heart disease before HTx, use of cyclosporine rather than tacrolimus, and increased length of follow‐up were associated with cancer. Upon multivariable analysis, ischemic heart disease (OR 2.70 [1.19–6.11], p = 0.017) and length of follow‐up (OR 1.02 [1.00–1.04], p = 0.007) were independently associated with cancer occurrence. Cox regression revealed a higher risk of mortality among patients with cancer (HR 3.400, [2.026–5.709], p < 0.001). HTx recipients with prior ischemic cardiomyopathy and a longer survival time after transplant show a higher risk of developing cancer. Cancer significantly impairs post‐transplant survival.
- 25 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (8) , e70243
Open AccessConditions Associated With the Onset of Cancer After Heart Transplant: Longitudinal Study in 335 Recipients
Cancer is among the major causes of death after heart transplant (HTx). Risk factors for cancer occurrence in this setting are not well established. This was a retrospective observational study of patients who underwent HTx between 2006 and 2019 and were followed up until May 2024. Clinical variables possibly associated with cancer were assessed with univariable and multivariable analyses. Survival analysis was carried out drawing Kaplan Meier curves and a Cox regression with time‐varying covariates were performed to overcome the immortal‐time‐bias. Three‐hundred‐thirty‐five HTx recipients were included, of whom 42 (12.5%) developed cancer after a median of 6.3 years. In univariable analysis, older age at HTx, smoking history, alcohol use, male sex, ischemic heart disease before HTx, use of cyclosporine rather than tacrolimus, and increased length of follow‐up were associated with cancer. Upon multivariable analysis, ischemic heart disease (OR 2.70 [1.19–6.11], p = 0.017) and length of follow‐up (OR 1.02 [1.00–1.04], p = 0.007) were independently associated with cancer occurrence. Cox regression revealed a higher risk of mortality among patients with cancer (HR 3.400, [2.026–5.709], p < 0.001). HTx recipients with prior ischemic cardiomyopathy and a longer survival time after transplant show a higher risk of developing cancer. Cancer significantly impairs post‐transplant survival.
- 1 September 2024
- Published by Hogrefe Publishing Group in Vasa
- Vol. 53 (5) , 358-360
Inferior vena cava filter implantation according to strength of clinical indication
- 1 September 2024
- Published by Hogrefe Publishing Group in Vasa
- Vol. 53 (5) , 358-360
Inferior vena cava filter implantation according to strength of clinical indication